Enter your search terms:
Top

Strong pipeline of products with therapeutic benefits

Aquestive is the undisputed leader in developing and delivering medications via film through our PharmFilm technology.  Building on our success, we now have a robust CNS and complex molecule portfolio.  We continuously strive to identify therapeutic areas where are our proprietary technologies can help improve patient outcomes.

Program Molecule Indication Formulation Pre-Clinical Phase 1 Phase 2 Phase 3 Filed Marketed
CNS Programs
AQST-120 clobazam Lennox-Gastaut syndrome
 
AQST-203 diazepam Acute Repetitive Seizures
 
AQST-117 riluzole ALS
 
Complex Molecule Programs
AQST-108 epinephrine Anaphylaxis
 
AQST-305 octreotide Acromegaly / Carcinoid Syndrome
 
Partnered Programs
Suboxone (Partner: Indivior) buprenorphine / naloxone Opioid Dependence
 
Zuplenz (Partner: Midatech) ondansetron CINV / PINV
 
APL-130277 (Partner: Sunovion) apomorphine Parkinson’s Disease
 
AQST-119 tadalafil Erectile Dysfunction / BPH
 

CNS Programs

AQST-120

+

Molecule: clobazam

Indication: Lennox-Gestaut syndrome

Phase: filed

AQST-203

+

Molecule: diazepam

Indication: acute repetitive seizures

Phase: 3

AQST-117

+

Molecule: riluzole

Indication: ALS

Phase: 3

Complex Molecule Programs

AQST-108

+

Molecule: epinephrine

Indication: Anaphalaxis

Phase: 1

AQST-305

+

Molecule: octreotide

Indication: Acromegaly / Carcinoid Syndrome

Phase: 1

Partnered Programs

Suboxone

+

Molecule: buprenorphine / naloxone

Indication: Opioid Dependence

Phase: marketed

Partner: Indivior

Zuplenz

+

Molecule: ondansetron

Indication: CINV / PINV

Phase: filed

Partner: Midatech

APL-130277

+

Molecule: apomorphine

Indication: Parkinson’s Disease

Phase: 3

Partner: Sunovion

AQST-119

+

Molecule: tadalafil

Indication: Erectile Dysfunction / BPH

Phase: filed

Partner: Actively pursuing partnerships

Latest comments

Sorry, the comment form is closed at this time.